Aurinia Pharmaceuticals (AUPH) Research & Development (2020 - 2026)

Aurinia Pharmaceuticals has reported Research & Development for 7 years, with the latest figure at $7.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 30.07% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $34.2 million (up 63.19% YoY), and the FY2025 full-year result was $32.5 million, up 56.39% from the prior year.
• Research & Development for Q1 2026 stood at $7.5 million, down from $10.9 million in the prior quarter.
• The five-year high for Research & Development was $13.6 million in Q3 2023, with the low at $3.0 million in Q3 2024.
• Historically, Research & Development has averaged $8.6 million across 5 years, with a median of $8.4 million in 2025.
• Annual changes were most pronounced in 2023 — Research & Development surged 228.95% — and 2024, when it slumped 77.6%.
• Aurinia Pharmaceuticals' Research & Development stood at $9.9 million in 2022, then gained by 3.63% to $10.2 million in 2023, then dropped by 20.74% to $8.1 million in 2024, then jumped by 34.39% to $10.9 million in 2025, then slumped by 31.44% to $7.5 million in 2026.
• The last three Research & Development figures came in at $7.5 million (Q1 2026), $10.9 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.